Evidence map›Paper›PMID 41196060›Full record

ArticleJournal of virology2025

Replication-driven HBV cccDNA loss in chimeric mice with humanized livers.

Bai-Hua Zhang, Yuanping Zhou, Stephen Horrigan, Fabien Zoulim, Jianming Hu, Yong-Yuan Zhang

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination.Molecular therapy. Methods & clinical development · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Bai-Hua ZhangVirology, HBVtech, Rockville, Maryland, USA.ORCID 0009-0002-1850-0233
Yuanping ZhouDepartment of Infectious Diseases, Nafang Hospital, Southern Medical University, Guangzhou, China.
Stephen HorriganPreclinical Department, Noble Life Sciences, Skysville, Maryland, USA.
Fabien ZoulimUMR PaThLiv U1350, INSERM, Université Claude Bernard Lyon 1, Lyon Hepatology Institute, Hospices Civils de Lyon, Lyon, France.
Jianming HuDepartment of Microbiology and Immunology, Penn State College of Medicine, Hershey, Pennsylvania, USA.ORCID 0000-0002-3967-2133
Yong-Yuan ZhangVirology, HBVtech, Rockville, Maryland, USA.ORCID 0000-0001-9337-1553

Funding

Mechanisms of Hepadnavirus Assembly and ReplicationR37AI043453 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI Jianming Hu · 2018 to 2026
$3.8M
ANTIVIRAL DRUGS TO CURE CHRONIC HEPATITIS B VIRUS INFECTION75N93022C00042 · NIAID · HBVTECH · PI ZHANG, YANG-YUAN · 2022 to 2023
$1.5M
SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES75N93020C00042 · NIAID · ANTAGEN PHARMACEUTICALS, INC. · PI GAO, WENDA · 2020 to 2020
$600k
Development of a Novel HBV Drug75N93020C00045 · NIAID · HBVTECH · PI ZHANG, YONG-YUAN · 2020 to 2021
$306k
A New HBV Drug For Establishing Durable Antiviral Efficacy of HBV TreatmentR43AI155066 · NIAID · HBVTECH · PI ZHANG, YONG-YUAN · 2021 to 2021
$300k
NIAID NIH HHS 75N93020C00042NIAID NIH HHS 75N93020C00045NIAID NIH HHS 75N93022C00042NIAID NIH HHS R37 AI043453NIAID NIH HHS R43 AI155066
6 · The paper itself

Abstract

Hepatitis B virus (HBV) infection depends on the establishment of covalently closed circular DNA (cccDNA) and can be either transient or persistent. Persistent infection requires a noncytopathic viral phenotype, primarily achieved by limiting replication in infected cells. This study aimed to understand how most HBV-infected cells can avoid cytopathic consequences despite robust replication. Using chimeric mice with humanized livers, we assessed HBV replication kinetics and observed a progressive accumulation of viral products from early stages up to peak infection in infected cells, but the accumulation stopped increasing upon reaching the persistence phase, possibly resulting from the inhibition of HBV replication. We then examined HBV products, including cccDNA, transcription, and viral protein levels, to identify the potential point of inhibition, finding no clear suppression of viral transcription or protein synthesis. Quantitative analysis of cccDNA levels in bulk cells, single nuclei, and individual HBsAg-positive cells revealed that cccDNA was undetectable in a portion of infected cells. Our findings raise the possibility that infected cells may spontaneously clear cccDNA. This would stop HBV replication at its root and avoid the potential cytopathic consequences in infected cells due to uncontrolled viral replication. These results suggest that efficient cccDNA elimination might be achievable without directly targeting existing cccDNA.IMPORTANCEThe primary barrier to curing chronic HBV infection is the persistence of covalently closed circular DNA (cccDNA), which is traditionally considered stable within infected cells. However, clinical observations have revealed that cccDNA can undergo frequent clearance and replacement in patients with chronic HBV infection. Building on these observations, our study demonstrated that cccDNA was undetectable in a portion of HBV-infected cells at different timepoints after peak infection in chimeric mice with humanized livers, suggesting that spontaneous cccDNA clearance may occur. These findings align with clinical data and indicate that effective cccDNA elimination may be possible without the need to target cccDNA itself directly.

Indexed as

DNA, CircularDNA, ViralHepatitis BHepatitis B virusLiverVirus ReplicationAnimalsChimeraHepatocytesHumansMiceDNA, CircularDNA, ViralcccDNA clearance and replenishmentcytopathic effectsHBV replicationpersistent HBV infection

Identifiers

PMID41196060
PMCPMC12645921

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.